+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Neurodegenerative Drugs - Global Strategic Business Report

  • PDF Icon

    Report

  • 344 Pages
  • December 2024
  • Region: Global
  • Global Industry Analysts, Inc
  • ID: 1227799
The global market for Neurodegenerative Drugs is estimated at US$42.8 Billion in 2023 and is projected to reach US$57.3 Billion by 2030, growing at a CAGR of 4.2% from 2023 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions.

Key Insights:

  • Market Growth: Understand the significant growth trajectory of the Multiple Sclerosis Drugs segment, which is expected to reach US$38.3 Billion by 2030 with a CAGR of a 4.6%. The Parkinson`s Drugs segment is also set to grow at 3.7% CAGR over the next 7 years.
  • Regional Analysis: Gain insights into the U.S. market, estimated at $11.6 Billion in 2023, and China, forecasted to grow at an impressive 7.3% CAGR to reach $12.1 Billion by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.

Why You Should Buy This Report:

  • Detailed Market Analysis: Access a thorough analysis of the Global Neurodegenerative Drugs Market, covering all major geographic regions and market segments.
  • Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
  • Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Neurodegenerative Drugs Market.
  • Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.

Key Questions Answered:

  • How is the Global Neurodegenerative Drugs Market expected to evolve by 2030?
  • What are the main drivers and restraints affecting the market?
  • Which market segments will grow the most over the forecast period?
  • How will market shares for different regions and segments change by 2030?
  • Who are the leading players in the market, and what are their prospects?

Report Features:

  • Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2023 to 2030.
  • In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
  • Company Profiles: Coverage of major players such as Biogen, Inc., Boehringer Ingelheim GmbH, Daiichi Sankyo Co., Ltd., and more.
  • Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.

Select Competitors (Total 163 Featured):

  • Biogen, Inc.
  • Boehringer Ingelheim GmbH
  • Daiichi Sankyo Co., Ltd.
  • Eisai Co., Ltd.
  • F. Hoffmann-La Roche AG
  • GlaxoSmithKline PLC
  • H. Lundbeck A/S
  • Merck KGaA
  • Mitsubishi Tanabe Pharma Corporation
  • Novartis International AG
  • Pfizer, Inc.
  • Reata Pharmaceuticals, Inc.
  • Sage Therapeutics, Inc.
  • Sanofi
  • Teva Pharmaceutical Industries Ltd.
  • UCB SA

MarketGlass Platform

Our reports are enhanced by the MarketGlass platform, which brings together industry experts and influencers to provide high-quality, accurate insights. This unique platform allows us to gather comprehensive data and market perspectives, ensuring you receive the most reliable and detailed analysis available.

Table of Contents

I. METHODOLOGYII. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Neurodegenerative Drugs - Global Key Competitors Percentage Market Share in 2024 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • Global Economic Update
2. FOCUS ON SELECT PLAYERS3. MARKET TRENDS & DRIVERS
4. GLOBAL MARKET PERSPECTIVE
  • Table 1: World Recent Past, Current & Future Analysis for Neurodegenerative Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 2: World Historic Review for Neurodegenerative Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 3: World 16-Year Perspective for Neurodegenerative Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
  • Table 4: World Recent Past, Current & Future Analysis for Multiple Sclerosis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 5: World Historic Review for Multiple Sclerosis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 6: World 16-Year Perspective for Multiple Sclerosis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • Table 7: World Recent Past, Current & Future Analysis for Parkinson`s by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 8: World Historic Review for Parkinson`s by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 9: World 16-Year Perspective for Parkinson`s by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • Table 10: World Recent Past, Current & Future Analysis for Alzheimer`s by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 11: World Historic Review for Alzheimer`s by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 12: World 16-Year Perspective for Alzheimer`s by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • Table 13: World Recent Past, Current & Future Analysis for Spinal Muscular Atrophy (SMA) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 14: World Historic Review for Spinal Muscular Atrophy (SMA) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 15: World 16-Year Perspective for Spinal Muscular Atrophy (SMA) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • Table 16: World Recent Past, Current & Future Analysis for Other Disease Indications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 17: World Historic Review for Other Disease Indications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 18: World 16-Year Perspective for Other Disease Indications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • Table 19: World Neurodegenerative Drugs Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
III. MARKET ANALYSIS
UNITED STATES
  • Neurodegenerative Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
  • Table 20: USA Recent Past, Current & Future Analysis for Neurodegenerative Drugs by Disease Indication - Multiple Sclerosis, Parkinson`s, Alzheimer`s, Spinal Muscular Atrophy (SMA) and Other Disease Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 21: USA Historic Review for Neurodegenerative Drugs by Disease Indication - Multiple Sclerosis, Parkinson`s, Alzheimer`s, Spinal Muscular Atrophy (SMA) and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 22: USA 16-Year Perspective for Neurodegenerative Drugs by Disease Indication - Percentage Breakdown of Value Sales for Multiple Sclerosis, Parkinson`s, Alzheimer`s, Spinal Muscular Atrophy (SMA) and Other Disease Indications for the Years 2014, 2024 & 2030
CANADA
  • Table 23: Canada Recent Past, Current & Future Analysis for Neurodegenerative Drugs by Disease Indication - Multiple Sclerosis, Parkinson`s, Alzheimer`s, Spinal Muscular Atrophy (SMA) and Other Disease Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 24: Canada Historic Review for Neurodegenerative Drugs by Disease Indication - Multiple Sclerosis, Parkinson`s, Alzheimer`s, Spinal Muscular Atrophy (SMA) and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 25: Canada 16-Year Perspective for Neurodegenerative Drugs by Disease Indication - Percentage Breakdown of Value Sales for Multiple Sclerosis, Parkinson`s, Alzheimer`s, Spinal Muscular Atrophy (SMA) and Other Disease Indications for the Years 2014, 2024 & 2030
JAPAN
  • Neurodegenerative Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
  • Table 26: Japan Recent Past, Current & Future Analysis for Neurodegenerative Drugs by Disease Indication - Multiple Sclerosis, Parkinson`s, Alzheimer`s, Spinal Muscular Atrophy (SMA) and Other Disease Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 27: Japan Historic Review for Neurodegenerative Drugs by Disease Indication - Multiple Sclerosis, Parkinson`s, Alzheimer`s, Spinal Muscular Atrophy (SMA) and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 28: Japan 16-Year Perspective for Neurodegenerative Drugs by Disease Indication - Percentage Breakdown of Value Sales for Multiple Sclerosis, Parkinson`s, Alzheimer`s, Spinal Muscular Atrophy (SMA) and Other Disease Indications for the Years 2014, 2024 & 2030
CHINA
  • Neurodegenerative Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
  • Table 29: China Recent Past, Current & Future Analysis for Neurodegenerative Drugs by Disease Indication - Multiple Sclerosis, Parkinson`s, Alzheimer`s, Spinal Muscular Atrophy (SMA) and Other Disease Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 30: China Historic Review for Neurodegenerative Drugs by Disease Indication - Multiple Sclerosis, Parkinson`s, Alzheimer`s, Spinal Muscular Atrophy (SMA) and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 31: China 16-Year Perspective for Neurodegenerative Drugs by Disease Indication - Percentage Breakdown of Value Sales for Multiple Sclerosis, Parkinson`s, Alzheimer`s, Spinal Muscular Atrophy (SMA) and Other Disease Indications for the Years 2014, 2024 & 2030
EUROPE
  • Neurodegenerative Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
  • Table 32: Europe Recent Past, Current & Future Analysis for Neurodegenerative Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 33: Europe Historic Review for Neurodegenerative Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 34: Europe 16-Year Perspective for Neurodegenerative Drugs by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
  • Table 35: Europe Recent Past, Current & Future Analysis for Neurodegenerative Drugs by Disease Indication - Multiple Sclerosis, Parkinson`s, Alzheimer`s, Spinal Muscular Atrophy (SMA) and Other Disease Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 36: Europe Historic Review for Neurodegenerative Drugs by Disease Indication - Multiple Sclerosis, Parkinson`s, Alzheimer`s, Spinal Muscular Atrophy (SMA) and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 37: Europe 16-Year Perspective for Neurodegenerative Drugs by Disease Indication - Percentage Breakdown of Value Sales for Multiple Sclerosis, Parkinson`s, Alzheimer`s, Spinal Muscular Atrophy (SMA) and Other Disease Indications for the Years 2014, 2024 & 2030
FRANCE
  • Neurodegenerative Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
  • Table 38: France Recent Past, Current & Future Analysis for Neurodegenerative Drugs by Disease Indication - Multiple Sclerosis, Parkinson`s, Alzheimer`s, Spinal Muscular Atrophy (SMA) and Other Disease Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 39: France Historic Review for Neurodegenerative Drugs by Disease Indication - Multiple Sclerosis, Parkinson`s, Alzheimer`s, Spinal Muscular Atrophy (SMA) and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 40: France 16-Year Perspective for Neurodegenerative Drugs by Disease Indication - Percentage Breakdown of Value Sales for Multiple Sclerosis, Parkinson`s, Alzheimer`s, Spinal Muscular Atrophy (SMA) and Other Disease Indications for the Years 2014, 2024 & 2030
GERMANY
  • Neurodegenerative Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
  • Table 41: Germany Recent Past, Current & Future Analysis for Neurodegenerative Drugs by Disease Indication - Multiple Sclerosis, Parkinson`s, Alzheimer`s, Spinal Muscular Atrophy (SMA) and Other Disease Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 42: Germany Historic Review for Neurodegenerative Drugs by Disease Indication - Multiple Sclerosis, Parkinson`s, Alzheimer`s, Spinal Muscular Atrophy (SMA) and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 43: Germany 16-Year Perspective for Neurodegenerative Drugs by Disease Indication - Percentage Breakdown of Value Sales for Multiple Sclerosis, Parkinson`s, Alzheimer`s, Spinal Muscular Atrophy (SMA) and Other Disease Indications for the Years 2014, 2024 & 2030
ITALY
  • Table 44: Italy Recent Past, Current & Future Analysis for Neurodegenerative Drugs by Disease Indication - Multiple Sclerosis, Parkinson`s, Alzheimer`s, Spinal Muscular Atrophy (SMA) and Other Disease Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 45: Italy Historic Review for Neurodegenerative Drugs by Disease Indication - Multiple Sclerosis, Parkinson`s, Alzheimer`s, Spinal Muscular Atrophy (SMA) and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 46: Italy 16-Year Perspective for Neurodegenerative Drugs by Disease Indication - Percentage Breakdown of Value Sales for Multiple Sclerosis, Parkinson`s, Alzheimer`s, Spinal Muscular Atrophy (SMA) and Other Disease Indications for the Years 2014, 2024 & 2030
UNITED KINGDOM
  • Neurodegenerative Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
  • Table 47: UK Recent Past, Current & Future Analysis for Neurodegenerative Drugs by Disease Indication - Multiple Sclerosis, Parkinson`s, Alzheimer`s, Spinal Muscular Atrophy (SMA) and Other Disease Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 48: UK Historic Review for Neurodegenerative Drugs by Disease Indication - Multiple Sclerosis, Parkinson`s, Alzheimer`s, Spinal Muscular Atrophy (SMA) and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 49: UK 16-Year Perspective for Neurodegenerative Drugs by Disease Indication - Percentage Breakdown of Value Sales for Multiple Sclerosis, Parkinson`s, Alzheimer`s, Spinal Muscular Atrophy (SMA) and Other Disease Indications for the Years 2014, 2024 & 2030
SPAIN
  • Table 50: Spain Recent Past, Current & Future Analysis for Neurodegenerative Drugs by Disease Indication - Multiple Sclerosis, Parkinson`s, Alzheimer`s, Spinal Muscular Atrophy (SMA) and Other Disease Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 51: Spain Historic Review for Neurodegenerative Drugs by Disease Indication - Multiple Sclerosis, Parkinson`s, Alzheimer`s, Spinal Muscular Atrophy (SMA) and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 52: Spain 16-Year Perspective for Neurodegenerative Drugs by Disease Indication - Percentage Breakdown of Value Sales for Multiple Sclerosis, Parkinson`s, Alzheimer`s, Spinal Muscular Atrophy (SMA) and Other Disease Indications for the Years 2014, 2024 & 2030
RUSSIA
  • Table 53: Russia Recent Past, Current & Future Analysis for Neurodegenerative Drugs by Disease Indication - Multiple Sclerosis, Parkinson`s, Alzheimer`s, Spinal Muscular Atrophy (SMA) and Other Disease Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 54: Russia Historic Review for Neurodegenerative Drugs by Disease Indication - Multiple Sclerosis, Parkinson`s, Alzheimer`s, Spinal Muscular Atrophy (SMA) and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 55: Russia 16-Year Perspective for Neurodegenerative Drugs by Disease Indication - Percentage Breakdown of Value Sales for Multiple Sclerosis, Parkinson`s, Alzheimer`s, Spinal Muscular Atrophy (SMA) and Other Disease Indications for the Years 2014, 2024 & 2030
REST OF EUROPE
  • Table 56: Rest of Europe Recent Past, Current & Future Analysis for Neurodegenerative Drugs by Disease Indication - Multiple Sclerosis, Parkinson`s, Alzheimer`s, Spinal Muscular Atrophy (SMA) and Other Disease Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 57: Rest of Europe Historic Review for Neurodegenerative Drugs by Disease Indication - Multiple Sclerosis, Parkinson`s, Alzheimer`s, Spinal Muscular Atrophy (SMA) and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 58: Rest of Europe 16-Year Perspective for Neurodegenerative Drugs by Disease Indication - Percentage Breakdown of Value Sales for Multiple Sclerosis, Parkinson`s, Alzheimer`s, Spinal Muscular Atrophy (SMA) and Other Disease Indications for the Years 2014, 2024 & 2030
ASIA-PACIFIC
  • Neurodegenerative Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
  • Table 59: Asia-Pacific Recent Past, Current & Future Analysis for Neurodegenerative Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 60: Asia-Pacific Historic Review for Neurodegenerative Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 61: Asia-Pacific 16-Year Perspective for Neurodegenerative Drugs by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
  • Table 62: Asia-Pacific Recent Past, Current & Future Analysis for Neurodegenerative Drugs by Disease Indication - Multiple Sclerosis, Parkinson`s, Alzheimer`s, Spinal Muscular Atrophy (SMA) and Other Disease Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 63: Asia-Pacific Historic Review for Neurodegenerative Drugs by Disease Indication - Multiple Sclerosis, Parkinson`s, Alzheimer`s, Spinal Muscular Atrophy (SMA) and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 64: Asia-Pacific 16-Year Perspective for Neurodegenerative Drugs by Disease Indication - Percentage Breakdown of Value Sales for Multiple Sclerosis, Parkinson`s, Alzheimer`s, Spinal Muscular Atrophy (SMA) and Other Disease Indications for the Years 2014, 2024 & 2030
AUSTRALIA
  • Neurodegenerative Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
INDIA
  • Neurodegenerative Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
SOUTH KOREAREST OF ASIA-PACIFIC
LATIN AMERICA
  • Neurodegenerative Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
ARGENTINABRAZILMEXICOREST OF LATIN AMERICA
MIDDLE EAST
  • Neurodegenerative Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
IRANISRAELSAUDI ARABIAUNITED ARAB EMIRATESREST OF MIDDLE EAST
AFRICA
  • Neurodegenerative Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
IV. COMPETITION

Companies Mentioned

  • Biogen, Inc.
  • Boehringer Ingelheim GmbH
  • Daiichi Sankyo Co., Ltd.
  • Eisai Co., Ltd.
  • F. Hoffmann-La Roche AG
  • GlaxoSmithKline PLC
  • H. Lundbeck A/S
  • Merck KGaA
  • Mitsubishi Tanabe Pharma Corporation
  • Novartis International AG
  • Pfizer, Inc.
  • Reata Pharmaceuticals, Inc.
  • Sage Therapeutics, Inc.
  • Sanofi
  • Teva Pharmaceutical Industries Ltd.
  • UCB SA

Table Information